HomeNewsBusinessADB, Wabag Sign Rs 200 crore debt facility to support sanitation and water security in India

ADB, Wabag Sign Rs 200 crore debt facility to support sanitation and water security in India

The board of Va Tech Wabag approved the proposal for fundraising by way of issuance of non-convertible debentures up to Rs 200 crore to ADB on a private placement basis.

November 25, 2022 / 19:15 IST
Story continues below Advertisement
(Representational image)
(Representational image)

The Asian Development Bank (ADB) has signed a $25 million or Rs 200 crore debt facility with VA Tech Wabag to support sanitation and water security through the development of new sewage treatment plants in India.

The board of Va Tech Wabag approved the proposal for fundraising by way of issuance of non-convertible debentures (NCDs) up to Rs 200 crore to ADB on a private placement basis.

Story continues below Advertisement

The issue could be done in one or more tranches/series, subject to necessary approvals, permissions, consents and sanctions as may be required. The tenure of the debentures is 5 years and 3 months.

This will be ADB’s first investment in a Water sector company in India and it will also provide technical assistance of up to $35,000 to enhance Wabag’s capacity to assess and mitigate environmental and social risks for future projects.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show